Profusa (NASDAQ:PFSA – Get Free Report) and Nanovibronix (NASDAQ:FEED – Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.
Insider & Institutional Ownership
9.8% of Profusa shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 11.4% of Profusa shares are owned by company insiders. Comparatively, 1.4% of Nanovibronix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Profusa and Nanovibronix”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Profusa | N/A | N/A | -$8.71 million | ($2.23) | -1.35 |
| Nanovibronix | $2.69 million | 1.15 | -$3.70 million | ($41.74) | -0.07 |
Nanovibronix has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Profusa has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for Profusa and Nanovibronix, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profusa | 1 | 0 | 0 | 0 | 1.00 |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Profusa and Nanovibronix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Profusa | N/A | N/A | -880.32% |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
Summary
Nanovibronix beats Profusa on 6 of the 10 factors compared between the two stocks.
About Profusa
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
